# A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

> **NCT05631093** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 553 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** ART
- **DRUG:** DOR/ISL

## Key facts

- **NCT ID:** NCT05631093
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-20
- **Primary completion:** 2024-10-10
- **Final completion:** 2028-07-11
- **Target enrollment:** 553 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05631093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05631093, "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05631093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*